Baker BROS. Advisors LP Has $16.24 Million Position in Contineum Therapeutics, Inc. $CTNM

Posted by Geri Gentry on Jun 18th, 2026

Baker BROS. Advisors LP grew its stake in shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM – Free Report) by 1,729.3% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,420,838 shares of the company’s stock after buying an additional 1,343,168 shares during the period. Baker BROS. Advisors LP owned approximately 4.87% of Contineum Therapeutics worth $16,240,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Geode Capital Management LLC increased its stake in Contineum Therapeutics by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 213,869 shares of the company’s stock valued at $2,446,000 after acquiring an additional 2,819 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Contineum Therapeutics in the fourth quarter valued at about $43,000. Strs Ohio bought a new stake in Contineum Therapeutics in the first quarter valued at about $27,000. Schonfeld Strategic Advisors LLC increased its stake in Contineum Therapeutics by 22.6% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 22,673 shares of the company’s stock valued at $259,000 after acquiring an additional 4,177 shares during the period. Finally, Bank of America Corp DE increased its stake in Contineum Therapeutics by 500.0% in the third quarter. Bank of America Corp DE now owns 7,236 shares of the company’s stock valued at $85,000 after acquiring an additional 6,030 shares during the period.

Contineum Therapeutics Trading Down 1.9%

Shares of Contineum Therapeutics stock opened at $12.16 on Thursday. The stock has a market capitalization of $454.66 million, a price-to-earnings ratio of -6.24 and a beta of 0.89. Contineum Therapeutics, Inc. has a 1-year low of $3.57 and a 1-year high of $16.33. The firm’s 50-day moving average price is $13.04 and its two-hundred day moving average price is $12.99.

Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.16. As a group, equities research analysts predict that Contineum Therapeutics, Inc. will post -1.68 EPS for the current year.

Analyst Upgrades and Downgrades

CTNM has been the topic of a number of analyst reports. Wall Street Zen raised shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Contineum Therapeutics in a research note on Monday, April 20th. Morgan Stanley upped their target price on shares of Contineum Therapeutics from $14.00 to $16.00 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Finally, Robert W. Baird upped their target price on shares of Contineum Therapeutics from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Friday, March 6th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Read Our Latest Analysis on Contineum Therapeutics

About Contineum Therapeutics

(Free Report)

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.